1. Home
  2. PBYI vs UFG Comparison

PBYI vs UFG Comparison

Compare PBYI & UFG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PBYI
  • UFG
  • Stock Information
  • Founded
  • PBYI 2010
  • UFG 2021
  • Country
  • PBYI United States
  • UFG Singapore
  • Employees
  • PBYI N/A
  • UFG N/A
  • Industry
  • PBYI Biotechnology: Pharmaceutical Preparations
  • UFG Oil Refining/Marketing
  • Sector
  • PBYI Health Care
  • UFG Energy
  • Exchange
  • PBYI Nasdaq
  • UFG Nasdaq
  • Market Cap
  • PBYI 145.3M
  • UFG 136.4M
  • IPO Year
  • PBYI N/A
  • UFG 2025
  • Fundamental
  • Price
  • PBYI $2.91
  • UFG $4.39
  • Analyst Decision
  • PBYI Strong Buy
  • UFG
  • Analyst Count
  • PBYI 1
  • UFG 0
  • Target Price
  • PBYI $7.00
  • UFG N/A
  • AVG Volume (30 Days)
  • PBYI 288.9K
  • UFG 166.1K
  • Earning Date
  • PBYI 02-27-2025
  • UFG 01-01-0001
  • Dividend Yield
  • PBYI N/A
  • UFG N/A
  • EPS Growth
  • PBYI 492.79
  • UFG N/A
  • EPS
  • PBYI 0.47
  • UFG 0.02
  • Revenue
  • PBYI $243,569,000.00
  • UFG $130,669,390.00
  • Revenue This Year
  • PBYI N/A
  • UFG N/A
  • Revenue Next Year
  • PBYI N/A
  • UFG N/A
  • P/E Ratio
  • PBYI $6.24
  • UFG $225.13
  • Revenue Growth
  • PBYI 6.30
  • UFG 129.69
  • 52 Week Low
  • PBYI $2.23
  • UFG $3.82
  • 52 Week High
  • PBYI $7.15
  • UFG $5.10
  • Technical
  • Relative Strength Index (RSI)
  • PBYI 48.76
  • UFG N/A
  • Support Level
  • PBYI $2.69
  • UFG N/A
  • Resistance Level
  • PBYI $2.98
  • UFG N/A
  • Average True Range (ATR)
  • PBYI 0.12
  • UFG 0.00
  • MACD
  • PBYI 0.01
  • UFG 0.00
  • Stochastic Oscillator
  • PBYI 58.11
  • UFG 0.00

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Share on Social Networks: